Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
67 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Plague - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Plague - Pipeline Review, H1 2015', provides an overview of the Plague's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Plague, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Plague and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Plague - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Plague and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Plague products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Plague pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons To Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Plague - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Plague pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Plague Overview 8 Therapeutics Development 9 Pipeline Products for Plague - Overview 9 Pipeline Products for Plague - Comparative Analysis 10 Plague - Therapeutics under Development by Companies 11 Plague - Therapeutics under Investigation by Universities/Institutes 12 Plague - Pipeline Products Glance 13 Clinical Stage Products 13 Early Stage Products 14 Unknown Stage Products 15 Plague - Products under Development by Companies 16 Plague - Products under Investigation by Universities/Institutes 17 Plague - Companies Involved in Therapeutics Development 18 Aradigm Corporation 18 Cellceutix Corporation 19 Grifols, S.A. 20 iBio, Inc. 21 Mucosis B.V. 22 Summit Corporation plc 23 Syntiron LLC 24 Tetraphase Pharmaceuticals Inc. 25 Plague - Therapeutics Assessment 26 Assessment by Monotherapy Products 26 Assessment by Combination Products 27 Assessment by Target 28 Assessment by Mechanism of Action 30 Assessment by Route of Administration 32 Assessment by Molecule Type 34 Drug Profiles 36 anthrax + plague vaccine - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 ARD-3100 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 ciprofloxacin hydrochloride - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 plague vaccine - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 plague vaccine - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 plague vaccine - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 plague vaccine - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 plague vaccine - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 plague vaccine - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 plague vaccine - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 plague vaccine - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 PMX-30016 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 pneumonic plaque vaccine - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Small Molecules to Inhibit Yoph Protein Tyrosine Phosphatase for Plague - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 SMT-15000 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 TP-271 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 yersinia pestis vaccine - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Yersinia pestis vaccine - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Plague - Recent Pipeline Updates 57 Plague - Dormant Projects 61 Plague - Discontinued Products 62 Plague - Product Development Milestones 63 Featured News & Press Releases 63 Nov 19, 2012: UK Scientists Report On Efficacy Of Aradigm's Lipoquin Against Pneumonic Plague 63 Jun 05, 2008: Computer Sciences Corporation's DynPort Vaccine Company To Continue Plague Vaccine Development 64 Nov 18, 2005: Computer Sciences Corporation's DynPort Vaccine Company Reaches Milestone In Plague Vaccine Clinical Trial 64 May 17, 2005: Wake Forest Scientists Find New Combination Vaccine Effective Against Plague 65 Jan 10, 2005: Computer Sciences Corporation's DynPort Vaccine Company Enters Clinical Trial For Plague Vaccine Candidate 65 Appendix 66 Methodology 66 Coverage 66 Secondary Research 66 Primary Research 66 Expert Panel Validation 66 Contact Us 66 Disclaimer 67
List of Tables Number of Products under Development for Plague, H1 2015 9 Number of Products under Development for Plague - Comparative Analysis, H1 2015 10 Number of Products under Development by Companies, H1 2015 11 Number of Products under Investigation by Universities/Institutes, H1 2015 12 Comparative Analysis by Clinical Stage Development, H1 2015 13 Comparative Analysis by Early Stage Development, H1 2015 14 Comparative Analysis by Unknown Stage Development, H1 2015 15 Products under Development by Companies, H1 2015 16 Products under Investigation by Universities/Institutes, H1 2015 17 Plague - Pipeline by Aradigm Corporation, H1 2015 18 Plague - Pipeline by Cellceutix Corporation, H1 2015 19 Plague - Pipeline by Grifols, S.A., H1 2015 20 Plague - Pipeline by iBio, Inc., H1 2015 21 Plague - Pipeline by Mucosis B.V., H1 2015 22 Plague - Pipeline by Summit Corporation plc, H1 2015 23 Plague - Pipeline by Syntiron LLC, H1 2015 24 Plague - Pipeline by Tetraphase Pharmaceuticals Inc., H1 2015 25 Assessment by Monotherapy Products, H1 2015 26 Assessment by Combination Products, H1 2015 27 Number of Products by Stage and Target, H1 2015 29 Number of Products by Stage and Mechanism of Action, H1 2015 31 Number of Products by Stage and Route of Administration, H1 2015 33 Number of Products by Stage and Molecule Type, H1 2015 35 Plague Therapeutics - Recent Pipeline Updates, H1 2015 57 Plague - Dormant Projects, H1 2015 61 Plague - Discontinued Products, H1 2015 62
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
